Date Title & Summary Additional Formats
July 27, 2021
Mubadala Invests in Global Biosimulation Leader Certara
PRINCETON, N.J. , July 27, 2021 (GLOBE NEWSWIRE) -- Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara . The investment aligns with Mubadala’s strategy of enabling
July 23, 2021
Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19
Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology PRINCETON, N.J. , July 23, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced that its Vaccine Simulator accurately predicted that eight
July 15, 2021
Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members
PRINCETON, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021 . The two additional appointments increase the company’s board of directors to
July 14, 2021
Certara to Report Second Quarter 2021 Financial Results on August 5, 2021
PRINCETON, N.J. , July 14, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2021 after the market close on Thursday, August 5, 2021 .
July 13, 2021
Certara Announces New Chief Human Resources Officer
Veteran HR leader brings 20+ years of human resources experience to the company’s executive team PRINCETON, N.J. , July 13, 2021 (GLOBE NEWSWIRE) -- Certara ® , a global leader in biosimulation, today announced that it has appointed Nicolette D. Sherman to the position of Chief Human Resources
July 8, 2021
Certara Announces Update of BaseCase Software, the Company’s Value Communication Platform
Major Release to Help Life Science Companies Maximize Go-to-Market Impact PRINCETON, N.J. , July 08, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the release of BaseCase software version 2021.06, which updates the value communication software platform to
June 23, 2021
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions
The PMDA enters 8th consecutive year of using Certara’s biosimulation software PRINCETON, N.J. , June 23, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s
June 14, 2021
Certara Appoints Dr. Carol Gallagher as New Independent Board Member
Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role PRINCETON, N.J. , June 14, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the addition of Carol Gallagher , Pharm.D., to its board of directors. Dr.
May 20, 2021
Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
PRINCETON, N.J. , May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery , Chief Executive Officer, and Andrew Schemick , Chief Financial Officer, will participate in the following virtual investor conferences: William
May 13, 2021
Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies
Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges PRINCETON, N.J. , May 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of
Displaying 1 - 10 of 23